EXACT SCIENCES CORP 4

Director Katherine S. Zanotti had 55,361 shares of Exact Sciences common stock cashed out at $105.00 per share in the Abbott merger, leaving her with no remaining shares.

On March 23, 2026, in connection with the closing of Abbott Laboratories’ cash acquisition of Exact Sciences Corporation at $105.00 per share, all 55,361 shares of Exact Sciences common stock beneficially owned (or deemed beneficially owned) by reporting person Katherine S. Zanotti, including 5,398 shares noted as subject to vesting or similar restrictions, were converted and cancelled in exchange for cash merger consideration. Following this merger-triggered disposition, Zanotti reported zero shares of Exact Sciences common stock owned, reflecting the company’s conversion into a wholly owned subsidiary of Abbott and the cash-out of her equity stake at the merger price.

Filing Facts

CIK

1124140

Ticker

EXAS

Form

4

Source Type

sec

Accession

0001193125-26-118747

Alert Tier

7